OrbiMed’s Neurogene NGNE Stock Holding History

OrbiMed’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-46,090	Closed	-$10.5M	–	146
2020 Q1	$10.5M	Buy	46,090 +1,090	+2%	+$224K	0.18%	85
2019 Q4	$11.1M	Buy	+45,000	New	+$4.48M	0.16%	81

Other funds holding NGNE

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

OrbiMed's NGNE Position: Q2 2020 in Review

OrbiMed sold out of Neurogene (NGNE) in Q2 2020, closing a stake of 46,090 shares — an estimated $10.5M sold.

OrbiMed first reported a position in NGNE in Q4 2019 and held it in 2 quarters. The position peaked at $11.1M in Q4 2019. 74 funds tracked by Wall St. Rank hold NGNE as of Q2 2020.

OrbiMed reported no remaining Neurogene position as of Q2 2020 after selling out during the quarter.
OrbiMed sold 46,090 Neurogene shares in Q2 2020, an estimated $10.5M.
OrbiMed first reported a position in Neurogene in Q4 2019 and held it in 2 quarters.
OrbiMed's Neurogene position peaked at $11.1M in Q4 2019.
74 funds tracked by Wall St. Rank held Neurogene as of Q2 2020.

Based on OrbiMed's 13F filing for Q2 2020, filed 14 Aug 2020.